We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
In dieser Ausgabe von Industry Voice spricht Anton Selesnew, Global Medical Director von BIOCAD, über den Impfstoff gegen das Coronavirus, den anspruchsvollsten und einen der teuersten Impfstoffe der Welt, der auf der eigenen Gentherapie-Plattform BIOCAD entwickelt wurde.
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
